PMID- 35399955
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20220531
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Impact of Baseline and Trajectory of Triglyceride-Glucose Index on Cardiovascular 
      Outcomes in Patients With Type 2 Diabetes Mellitus.
PG  - 858209
LID - 10.3389/fendo.2022.858209 [doi]
LID - 858209
AB  - BACKGROUND AND AIMS: This study aimed to evaluate the association of the 
      triglyceride-glucose (TyG) index with the cardiovascular incidence in patients 
      with type 2 diabetes mellitus (T2DM). METHODS AND RESULTS: Secondary analysis in 
      patients with long-lasting T2DM from the Action to Control Cardiovascular Risk in 
      Diabetes study was performed. The primary outcome was the first occurrence of 
      major adverse cardiovascular events (MACEs). The association between the baseline 
      and trajectories of the TyG index and MACEs was evaluated by Cox proportional 
      hazards regression analysis. During a median follow-up period of 8.8 years, 1,815 
      (17.8%) patients developed MACEs. After traditional cardiovascular risk factor 
      adjustments, each 1-standard deviation increase in the TyG index was associated 
      with a 19.00% higher MACE risk, similar to that in the TyG index quartile 
      characterization. Four distinct trajectories of TyG indexes were identified: low 
      (16.17%), moderate (40.01%), high (34.60%), and very high (9.30%). In 
      multivariate analysis, high and very high TyG index trajectories showed a greater 
      risk of future MACE incidence than the low TyG index trajectory. A similar 
      association was observed between the TyG index and the occurrence of coronary 
      heart disease. CONCLUSIONS: The baseline and trajectories of the TyG index were 
      significantly associated with the occurrence of MACEs in patients with T2DM. 
      CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: 
      NCT00000620.
CI  - Copyright (c) 2022 Tai, Fu, Zhang, Zhou, Xing and Wang.
FAU - Tai, Shi
AU  - Tai S
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, Changsha, China.
FAU - Fu, Liyao
AU  - Fu L
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Zhang, Ningjie
AU  - Zhang N
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Xing, Zhenhua
AU  - Xing Z
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, Changsha, China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT00000620
PT  - Clinical Study
PT  - Journal Article
DEP - 20220324
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Triglycerides)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Biomarkers
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Glucose
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - Triglycerides
PMC - PMC8987353
OTO - NOTNLM
OT  - cardiovascular disease
OT  - insulin resistance glycated hemoglobin
OT  - risk factors
OT  - triglyceride-glucose index
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/13 06:00
PMCR- 2022/01/01
CRDT- 2022/04/11 05:20
PHST- 2022/01/21 00:00 [received]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/04/11 05:20 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.858209 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Mar 24;13:858209. doi: 
      10.3389/fendo.2022.858209. eCollection 2022.